|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: PIK3C2B |
Gene summary for PIK3C2B |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | PIK3C2B | Gene ID | 5287 |
| Gene name | phosphatidylinositol-4-phosphate 3-kinase catalytic subunit type 2 beta | |
| Gene Alias | C2-PI3K | |
| Cytomap | 1q32.1 | |
| Gene Type | protein-coding | GO ID | GO:0006629 | UniProtAcc | A2RUF7 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 5287 | PIK3C2B | HTA11_2487_2000001011 | Human | Colorectum | SER | 6.15e-03 | 4.37e-01 | -0.1808 |
| 5287 | PIK3C2B | HTA11_1938_2000001011 | Human | Colorectum | AD | 5.89e-03 | 4.45e-01 | -0.0811 |
| 5287 | PIK3C2B | HTA11_347_2000001011 | Human | Colorectum | AD | 9.62e-09 | 4.96e-01 | -0.1954 |
| 5287 | PIK3C2B | HTA11_83_2000001011 | Human | Colorectum | SER | 2.26e-02 | 5.04e-01 | -0.1526 |
| 5287 | PIK3C2B | HTA11_696_2000001011 | Human | Colorectum | AD | 5.90e-12 | 5.72e-01 | -0.1464 |
| 5287 | PIK3C2B | HTA11_866_2000001011 | Human | Colorectum | AD | 3.15e-09 | 4.10e-01 | -0.1001 |
| 5287 | PIK3C2B | HTA11_1391_2000001011 | Human | Colorectum | AD | 3.70e-06 | 5.55e-01 | -0.059 |
| 5287 | PIK3C2B | HTA11_7696_3000711011 | Human | Colorectum | AD | 8.86e-07 | 3.32e-01 | 0.0674 |
| 5287 | PIK3C2B | HTA11_99999965062_69753 | Human | Colorectum | MSI-H | 9.14e-03 | 9.26e-01 | 0.3487 |
| 5287 | PIK3C2B | A015-C-203 | Human | Colorectum | FAP | 3.50e-13 | -2.03e-01 | -0.1294 |
| 5287 | PIK3C2B | A002-C-201 | Human | Colorectum | FAP | 3.44e-06 | -1.96e-01 | 0.0324 |
| 5287 | PIK3C2B | A001-C-108 | Human | Colorectum | FAP | 9.55e-05 | -1.14e-01 | -0.0272 |
| 5287 | PIK3C2B | A002-C-205 | Human | Colorectum | FAP | 5.55e-11 | -3.19e-01 | -0.1236 |
| 5287 | PIK3C2B | A015-C-006 | Human | Colorectum | FAP | 1.88e-05 | -1.99e-01 | -0.0994 |
| 5287 | PIK3C2B | A015-C-106 | Human | Colorectum | FAP | 2.71e-02 | -1.42e-01 | -0.0511 |
| 5287 | PIK3C2B | A002-C-114 | Human | Colorectum | FAP | 2.62e-07 | -1.62e-01 | -0.1561 |
| 5287 | PIK3C2B | A015-C-104 | Human | Colorectum | FAP | 5.89e-12 | -1.97e-01 | -0.1899 |
| 5287 | PIK3C2B | A001-C-014 | Human | Colorectum | FAP | 1.89e-03 | -2.61e-01 | 0.0135 |
| 5287 | PIK3C2B | A002-C-016 | Human | Colorectum | FAP | 3.71e-06 | -2.28e-01 | 0.0521 |
| 5287 | PIK3C2B | A015-C-002 | Human | Colorectum | FAP | 6.06e-05 | -2.39e-01 | -0.0763 |
| Page: 1 2 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:0048017 | Colorectum | AD | inositol lipid-mediated signaling | 53/3918 | 182/18723 | 5.35e-03 | 3.52e-02 | 53 |
| GO:0048015 | Colorectum | AD | phosphatidylinositol-mediated signaling | 52/3918 | 178/18723 | 5.37e-03 | 3.54e-02 | 52 |
| GO:0006650 | Colorectum | AD | glycerophospholipid metabolic process | 83/3918 | 306/18723 | 5.40e-03 | 3.55e-02 | 83 |
| GO:0006644 | Colorectum | AD | phospholipid metabolic process | 101/3918 | 383/18723 | 5.80e-03 | 3.67e-02 | 101 |
| GO:0045017 | Colorectum | AD | glycerolipid biosynthetic process | 69/3918 | 252/18723 | 8.33e-03 | 4.88e-02 | 69 |
| GO:0046486 | Colorectum | SER | glycerolipid metabolic process | 82/2897 | 392/18723 | 2.26e-03 | 2.17e-02 | 82 |
| GO:00066441 | Colorectum | SER | phospholipid metabolic process | 79/2897 | 383/18723 | 3.94e-03 | 3.24e-02 | 79 |
| GO:00480171 | Colorectum | SER | inositol lipid-mediated signaling | 42/2897 | 182/18723 | 4.36e-03 | 3.49e-02 | 42 |
| GO:00450171 | Colorectum | SER | glycerolipid biosynthetic process | 55/2897 | 252/18723 | 4.47e-03 | 3.56e-02 | 55 |
| GO:00480151 | Colorectum | SER | phosphatidylinositol-mediated signaling | 41/2897 | 178/18723 | 4.97e-03 | 3.86e-02 | 41 |
| GO:00066501 | Colorectum | SER | glycerophospholipid metabolic process | 64/2897 | 306/18723 | 6.41e-03 | 4.60e-02 | 64 |
| GO:0008654 | Colorectum | FAP | phospholipid biosynthetic process | 54/2622 | 253/18723 | 8.88e-04 | 9.08e-03 | 54 |
| GO:00066502 | Colorectum | FAP | glycerophospholipid metabolic process | 62/2622 | 306/18723 | 1.54e-03 | 1.38e-02 | 62 |
| GO:00066442 | Colorectum | FAP | phospholipid metabolic process | 74/2622 | 383/18723 | 2.24e-03 | 1.83e-02 | 74 |
| GO:0046474 | Colorectum | FAP | glycerophospholipid biosynthetic process | 44/2622 | 211/18723 | 3.98e-03 | 2.76e-02 | 44 |
| GO:00450172 | Colorectum | FAP | glycerolipid biosynthetic process | 50/2622 | 252/18723 | 6.32e-03 | 3.95e-02 | 50 |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa05132 | Colorectum | AD | Salmonella infection | 102/2092 | 249/8465 | 7.65e-09 | 1.28e-07 | 8.17e-08 | 102 |
| hsa051321 | Colorectum | AD | Salmonella infection | 102/2092 | 249/8465 | 7.65e-09 | 1.28e-07 | 8.17e-08 | 102 |
| hsa051322 | Colorectum | SER | Salmonella infection | 77/1580 | 249/8465 | 1.56e-06 | 2.35e-05 | 1.71e-05 | 77 |
| hsa051323 | Colorectum | SER | Salmonella infection | 77/1580 | 249/8465 | 1.56e-06 | 2.35e-05 | 1.71e-05 | 77 |
| hsa051326 | Colorectum | MSI-H | Salmonella infection | 43/797 | 249/8465 | 5.91e-05 | 8.33e-04 | 6.98e-04 | 43 |
| hsa051327 | Colorectum | MSI-H | Salmonella infection | 43/797 | 249/8465 | 5.91e-05 | 8.33e-04 | 6.98e-04 | 43 |
| hsa051328 | Colorectum | FAP | Salmonella infection | 67/1404 | 249/8465 | 2.04e-05 | 2.52e-04 | 1.53e-04 | 67 |
| hsa051329 | Colorectum | FAP | Salmonella infection | 67/1404 | 249/8465 | 2.04e-05 | 2.52e-04 | 1.53e-04 | 67 |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| PIK3C2B | SNV | Missense_Mutation | c.262G>A | p.Asp88Asn | p.D88N | O00750 | protein_coding | tolerated_low_confidence(0.06) | benign(0.015) | TCGA-A2-A0CL-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | cytoxan | SD | |
| PIK3C2B | SNV | Missense_Mutation | c.133N>A | p.Glu45Lys | p.E45K | O00750 | protein_coding | tolerated_low_confidence(0.06) | benign(0.005) | TCGA-A2-A1FX-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | taxotere | SD | |
| PIK3C2B | SNV | Missense_Mutation | novel | c.2977C>A | p.Gln993Lys | p.Q993K | O00750 | protein_coding | deleterious(0) | possibly_damaging(0.598) | TCGA-A7-A0DB-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | arimidex | SD |
| PIK3C2B | SNV | Missense_Mutation | c.4067N>G | p.Ser1356Cys | p.S1356C | O00750 | protein_coding | deleterious(0) | benign(0.215) | TCGA-A8-A06X-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| PIK3C2B | SNV | Missense_Mutation | rs770075841 | c.4886G>A | p.Arg1629Gln | p.R1629Q | O00750 | protein_coding | tolerated_low_confidence(0.07) | benign(0.001) | TCGA-A8-A09M-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Chemotherapy | paclitaxel | CR |
| PIK3C2B | SNV | Missense_Mutation | c.1196C>G | p.Ser399Cys | p.S399C | O00750 | protein_coding | tolerated(0.09) | probably_damaging(0.979) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
| PIK3C2B | SNV | Missense_Mutation | c.284C>T | p.Ser95Leu | p.S95L | O00750 | protein_coding | deleterious_low_confidence(0) | benign(0.037) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
| PIK3C2B | SNV | Missense_Mutation | novel | c.2528G>A | p.Arg843Gln | p.R843Q | O00750 | protein_coding | deleterious(0.01) | probably_damaging(0.957) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| PIK3C2B | SNV | Missense_Mutation | c.3644N>A | p.Gly1215Asp | p.G1215D | O00750 | protein_coding | deleterious(0) | benign(0.214) | TCGA-AO-A0J6-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD | |
| PIK3C2B | SNV | Missense_Mutation | novel | c.3475N>C | p.Trp1159Arg | p.W1159R | O00750 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-AR-A0TS-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| 5287 | PIK3C2B | PHOSPHATIDYLINOSITOL 3 KINASE, KINASE, CLINICALLY ACTIONABLE, ENZYME, DRUGGABLE GENOME | inhibitor | BYL719 | ALPELISIB | |
| 5287 | PIK3C2B | PHOSPHATIDYLINOSITOL 3 KINASE, KINASE, CLINICALLY ACTIONABLE, ENZYME, DRUGGABLE GENOME | inhibitor | BAY80-6946 | COPANLISIB | |
| 5287 | PIK3C2B | PHOSPHATIDYLINOSITOL 3 KINASE, KINASE, CLINICALLY ACTIONABLE, ENZYME, DRUGGABLE GENOME | inhibitor | GDC-0941 | PICTILISIB | |
| 5287 | PIK3C2B | PHOSPHATIDYLINOSITOL 3 KINASE, KINASE, CLINICALLY ACTIONABLE, ENZYME, DRUGGABLE GENOME | inhibitor | PKI-587 | GEDATOLISIB | |
| 5287 | PIK3C2B | PHOSPHATIDYLINOSITOL 3 KINASE, KINASE, CLINICALLY ACTIONABLE, ENZYME, DRUGGABLE GENOME | inhibitor | BEZ235 | DACTOLISIB | |
| 5287 | PIK3C2B | PHOSPHATIDYLINOSITOL 3 KINASE, KINASE, CLINICALLY ACTIONABLE, ENZYME, DRUGGABLE GENOME | inhibitor | 178102328 | PI-103 | |
| 5287 | PIK3C2B | PHOSPHATIDYLINOSITOL 3 KINASE, KINASE, CLINICALLY ACTIONABLE, ENZYME, DRUGGABLE GENOME | inhibitor | GDC-0980 | APITOLISIB | |
| 5287 | PIK3C2B | PHOSPHATIDYLINOSITOL 3 KINASE, KINASE, CLINICALLY ACTIONABLE, ENZYME, DRUGGABLE GENOME | inhibitor | BGJ398 | INFIGRATINIB | |
| 5287 | PIK3C2B | PHOSPHATIDYLINOSITOL 3 KINASE, KINASE, CLINICALLY ACTIONABLE, ENZYME, DRUGGABLE GENOME | inhibitor | 252827496 | ||
| 5287 | PIK3C2B | PHOSPHATIDYLINOSITOL 3 KINASE, KINASE, CLINICALLY ACTIONABLE, ENZYME, DRUGGABLE GENOME | inhibitor | XL-765 | VOXTALISIB |
| Page: 1 2 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |